Beta2-Integrins and Interacting Proteins in Leukocyte Trafficking, Immune Suppression, and Immunodeficiency Disease

**Susanna C. Fagerholm**, **Carla Guenther**, **Marc Llort Asens**, **Terhi Savinko** and **Liisa M. Uotila**

1. Molecular and Integrative Biosciences Research Program, Faculty of Bio- and Environmental Sciences, University of Helsinki, Helsinki, Finland.
2. Iho- ja Allergiasairaala, HUS, Helsinki, Finland.
3. Research Services, University of Helsinki, Helsinki, Finland.

Beta2-integrins are complex leukocyte-specific adhesion molecules that are essential for leukocyte (e.g., neutrophil, lymphocyte) trafficking, as well as for other immunological processes such as neutrophil phagocytosis and ROS production, and T cell activation. Intriguingly, however, they have also been found to negatively regulate cytokine responses, maturation, and migratory responses in myeloid cells such as macrophages and dendritic cells, revealing new, and unexpected roles of these molecules in immunity. Because of their essential role in leukocyte function, a lack of expression or function of beta2-integrins causes rare immunodeficiency syndromes, Leukocyte adhesion deficiency type I, and type III (LAD-I and LAD-III). LAD-I is caused by reduced or lost expression of beta2-integrins, whilst in LAD-III, beta2-integrins are expressed but dysfunctional because a major integrin cytoplasmic regulator, kindlin-3, is mutated. Interestingly, some LAD-related phenotypes such as periodontitis have recently been shown to be due to an uncontrolled inflammatory response rather than to an uncontrolled infection, as was previously thought. This review will focus on the recent advances concerning the regulation and functions of beta2-integrins in leukocyte trafficking, immune suppression, and immune deficiency disease.

**Keywords**: integrin, trafficking, kindlin-3, leukocyte adhesion deficiency, leukocyte adhesion cascade

**INTEGRINS AND INTEGRIN REGULATION**

Integrins are heterodimeric type I transmembrane proteins consisting of alpha and beta subunits (1). Integrins are expressed in all nucleated cells and play a key role in adhesion, cell communication, and migration. They mediate adhesion to the extracellular matrix, by binding to the RGD motif of fibronectin, collagen, and laminin, among others (2). Integrins in leukocytes also bind to soluble ligands such as the complement component iC3b, and to other cells, by binding to ICAMs (Intercellular adhesion molecules) and VCAM-1 (Vascular cell adhesion molecule) (3, 4). Additionally, integrins link to the actin cytoskeleton inside the cell and thereby connect the inside of the cell with the outside. Integrins have large extracellular domains which contain the ligand-binding sites, and short cytoplasmic domains which are important for integrin regulation. The ability of the integrin to
bind to ligands is regulated through conformational changes as well as by integrin clustering. Integrins can be found in three main conformational states: inactive (bent-closed), intermediate (extended-closed), and active state (extended-open) (5). The predominant state seems to be the inactive (bent-closed) state based on affinity and thermodynamics studies with K562 cells (alpha5beta1-integrins, bent-closed: 99.75%; extended-closed: 0.10%; extended-open: 0.15%) (6). The active conformation (extended-open) has a 4,000-fold increase in ligand affinity compared to the other two states (7). Also on resting peripheral T cells the vast majority of LFA-1 (Lymphocyte function-associated antigen-1, alphaLbeta2-integrin) appear to be in the inactive conformation, as stabilizing the active conformation leads to a 1,000-fold increase in affinity of the integrin (8). The LFA-1 conformational change (integrin extension) on the surface of migrating T cells has recently been directly measured by super-resolution microscopy [interferometric photoactivation, and localization microscopy (iPALM)] (9).

Integrin activation takes place upon cell stimulation through various cell surface receptors such as chemokine receptors or the T cell receptor. Cell stimulation triggers an inside-out signaling pathway that ultimately recruits cytoplasmic factors such as talin and kindlin to the NPxY motifs of the cytoplasmic tail of the integrin's beta-chain, which causes the cytoplasmic tails of the integrin subunits to separate (10) and switches the integrin to the active (extended-open) conformation (11, 12). Kindlin and talin connect the integrin to the actin cytoskeleton and stabilize the extended-open conformation of the integrin through actin cytoskeleton exerted tensile force (6, 13). In addition, many other proteins, such as 14-3-3 proteins, alpha-actinin, coronin 1A, cytohesin 1, filamin A, and Dok1 can interact directly with the integrin beta-chain and modulate integrin function (14–16). These interactions are often regulated by phosphorylation of the integrin beta-chain cytoplasmic domain (15–18).

In addition to their ability to respond to the environment through inside-out signaling, integrins can take part in a variety of signaling cascades following ligand binding (outside-in signaling). Integrins take part in the formation of adhesion complexes and focal adhesions in cells such as fibroblasts, modulation of actin cytoskeleton dynamics, cell migration, differentiation, proliferation, angiogenesis, and apoptosis (19).

### Beta2-Integrins in Leukocyte Trafficking

Beta2-integrins (CD11a/CD18, alphaLbeta2, LFA-1; CD11b/CD18, alphaMbeta2, Mac-1; CR3; CD11c/CD18, alphaXbeta2, p150.95, CR4; and CD11d/CD18, alphaDbeta2) are a subgroup of integrins which share a common beta2- or CD18-chain but have different alpha-chains and ligands. Beta2-integrins are expressed exclusively in leukocytes, but the different members have their own distinct expression pattern. CD11a/CD18 is expressed on all leukocytes, while CD11b/CD18, CD11c/CD18, and CD11d/CD18 are mainly expressed on myeloid cells, but at varying levels (19, 20). CD11a/CD18 has a more restricted ligand binding capacity than the other beta2-integrins, and binds ligands such as ICAM-1-5 found on the surface of other cells. In contrast, CD11b/CD18 is a very promiscuous integrin with more than 40 reported ligands, including ICAMs, iC3b, fibrinogen, RAGE (receptor for advanced glycation end products), and CD40L (20). Interestingly, ligand-specific blockade of CD11b/CD18 has recently been shown to protect against bacterial sepsis, while blocking all CD11b/CD18 functions potentiates it, showing that CD11b/CD18 indeed has very complicated roles in immunity due to its many ligands (21). In addition to leukocytes, beta2-integrins are also found in extracellular vesicles (EVs), and integrins in EVs may play novel roles in development of pathogenic conditions such as sepsis (22).

It is undisputed that beta2-integrins are of fundamental importance for leukocyte trafficking. This is because they are required for the firm adhesion to the endothelial layer surrounding the blood vessels under conditions of shear flow (blood flow) and for leukocyte extravasation into tissues (23). The leukocyte adhesion cascade (Figure 1) is a multistep process involving rolling, firm adhesion or arrest, spreading/crawling, and finally extravasation (24). This complex process is accomplished by several proteins acting in parallel and succession, as the leukocyte proceeds to its destination. Initially contacts between the leukocyte and the endothelial cells allows selectins and ICAM-1 on endothelial cells to mediate leukocyte rolling on the endothelium. The close contact between the cells during rolling allows the leukocyte to sense chemokines present on the endothelium. In neutrophils, both selectins and chemokine receptors activate beta2-integrins via a signaling pathway involving the small GTPase Rap1a and phosphatidylinositol-4-phosphate 5-kinase (PIP5K)90. The activation of beta2-integrins involves conversion into the intermediate affinity state that mediates slow rolling, followed by conversion into the high affinity state, which mediates leukocyte arrest (25). Both selectins and integrins can form slip bonds, whose lifetime is shortened by applied shear force, as well as catch bonds, which strengthen under shear force (26–28), inducing further changes downstream of the integrins. During these leukocyte-endothelial contacts numerous integrin-ligand bonds are continuously broken and formed and further reinforced by the recruitment of more integrins and downstream cytoskeletal proteins such as talin, kindlin-3, focal adhesion kinase, and paxillin to form adhesion complexes which strengthen cell adhesion and induce actin reorganization and cell spreading (26). Following adhesion, cells crawl along the endothelium looking for a suitable extravasation site, a process critically dependent on the beta2-integrin CD11b/CD18 (29). As integrins act as mechanosensors in cells (30), it is likely that integrins are also central for the subsequent steps of probing the endothelium for suitable points of exit, either through a paracellular or transcellular route.

Talin has long been known to be indispensable for leukocyte trafficking (31–34). More recently, also kindlin-3 and its interaction with the beta2-integrin tail has been shown to be vital for neutrophil and effector T cell firm adhesion under shear flow and for neutrophil and T cell trafficking in vivo (35–38), and for homing of progenitor T cells to the vascularized thymus.
The main roles of beta2-integrins in immune activation and suppression are described:

(A) Phagocytosis. Beta2-integrins mediate phagocytosis by binding to iC3b on the surface of complement-coated bacteria.

(B) Regulation of T cell activation by a dendritic cell. Beta2-integrins participate in the formation of an immunological synapse between a T cell and an antigen-presenting cell such as DC. This synapse stabilizes the interaction between and regulates signaling in the two participating cells.

(C) Target cell killing. Beta2-integrins participate in forming and maintaining an immunological synapse between a cytotoxic T cell and an infected cell.

(D) Target cell killing. Beta2-integrins participate in forming and maintaining an immunological synapse between a cytotoxic T cell and an infected cell.

(E) Restriction of DC migration and Th1 response. Proper beta2-integrin—cytoskeleton linkage controls DC maturation toward a migratory phenotype and restricts priming of Th1 cells.

(F) Restriction of B cell receptor signaling. Interaction of CD11b/CD18 and CD22 on the surface of an autoreactive B cell leads to constraint in BCR signaling. This decreases auto-reactive B cell proliferation and antibody production.

(G) Restriction of B cell receptor signaling. Interaction of CD11b/CD18 and CD22 on the surface of an autoreactive B cell leads to constraint in BCR signaling. This decreases auto-reactive B cell proliferation and antibody production.

(39). However, talin and kindlin-3 regulate different aspects of leukocyte trafficking. Talin is required for the conformational change of the integrin to the extended, intermediate affinity conformation which mediates slow rolling. In contrast, both talin and kindlin-3 are required for the induction of the high-affinity conformation, full integrin activation and neutrophil arrest. 

Frontiers in Immunology | www.frontiersin.org 3 February 2019 | Volume 10 | Article 254
38, 40). Recently, Src kinase-associated phosphoprotein 2 (Skap2) has been shown to be essential for the recruitment of talin and kindlin-3 to the beta2-integrin tail, and for neutrophil trafficking in vivo (41). Interestingly, a bent-open conformation of beta2-integrins has been reported on neutrophils, which limits neutrophil recruitment by binding to ICAM-1 in cis, but the molecular mechanisms regulating this process are currently unknown (42).

In contrast to talin and kindlin-3, filamin A has been suggested to negatively regulate integrin functions in vitro (15, 43, 44). However, it has also been reported to be required for platelet shear flow adhesion because it stabilizes the links between the plasma membrane and the underlying actin cytoskeleton (45). Recent studies utilizing T cell-specific filamin A-deficient mice have shown that filamin A is required for the optimal firm adhesion of T cells under shear flow conditions, trafficking of T cells into lymph nodes, and to the inflamed skin (46). These results demonstrate that in T cells, filamin A does not function as an integrin inhibitor but rather is required for cell trafficking in vivo. However, filamin A is not required for neutrophil adhesion under shear flow conditions, but instead filamin A-deficient neutrophils display enhanced adhesion, spreading, and defects in uropod retraction, thereby revealing cell-type specific functions of this integrin interacting protein (47, 48).

In contrast to leukocyte trafficking from blood stream to lymph nodes and tissues, leukocyte trafficking within tissues (e.g., in a confined 3D environment in the absence of shear flow) is a mechanistically different process that can occur even in the absence of integrins (49). In lymph nodes, integrins, and chemokine receptors contribute partly to naïve T cell migration speed (50). In this environment the integrin CD11a/CD18 (LFA-1) is required as a frictional interface with the substrate (the so-called “integrin clutch”) by generating traction forces, but does not mediate substantial adhesion to the substrate (50). In some cases, integrins can even restrict leukocyte migration in tissues. Indeed, the beta2-integrin-kindlin-3 interaction negatively regulates DC migration to lymph nodes both under steady state and inflammatory conditions (36, 51). beta2-integrins restrict DC migration through a downstream mechanism which involves regulation of the transcriptional program and migratory phenotype of these cells (Figure 1).

**BETA2-INTEGRINS IN OTHER IMMUNE-RELATED FUNCTIONS**

In addition to their fundamentally important role in leukocyte trafficking, beta2-integrins also mediate other cell-cell contacts that are essential for immunological processes (Figure 1). Beta2-integrins (e.g., CD11a/CD18-integrin; LFA-1) are central components of the immunological synapse which forms between an antigen presenting cell (APC) and a T cell [reviewed in Dustin (52)], between a B cell and a T cell (53) and between an NK cell and its target cell (54). In brief, the cell-cell interactions mediated by CD11a/CD18 on the T cell enables T cell activation, by binding to ICAM-1 on the APC. T cell sample antigens on dendritic cells in lymph nodes via short term contacts, termed kinases (52). When antigen is found, T cells stop migrating and form an immunological synapse with the dendritic cell (52). LFA-1 on the T cell binding to ICAM-1 on the DC play a crucial role in this structure. LFA-1, together with talin, kindlin-3, and Rap1, is positioned in the p-SMAC (peripheral supramolecular activation cluster), thereby stabilizing the interaction between the T cell receptor and peptide-MHC II at the center of the contact (c-SMAC) (52, 55). Optimal T cell activation in vivo requires talin and kindlin-3 to bind to LFA-1 (32, 56). Upon activation, LFA-1 can signal into the T cell and thereby contribute to T cell activation and polarization of the T cell response (57). For example, LFA-1 ligation in T cells has been shown to promote Th1 polarization through a pathway involving Erk and Akt-mediated GSK3beta-inhibition, in turn leading to activation of the Notch pathway (58), and LFA-1 can also be regulated by, and engage in crosstalk with TGF-beta signaling in T cells (59, 60). In addition, a role for an intracellular pool of beta2-integrins in T cell activation and differentiation has recently been reported (61).

In addition to T cell activation, CD11a/CD18 is involved in the killing of infected target cells by cytotoxic T cells, by stabilizing the contact between the T cell and the target cell, and by sealing the contact zone so that cytolytic granules cannot escape (57). LFA-1 furthermore plays a role in the generation of T cell memory (57), survival of T follicular helper cells (62) and regulatory T cells (63) and B cell-mediated antibody production, by mediating cell-cell contacts, but also by initiating intracellular signaling cascades (57, 64). LFA-1 is important for CD8+ T cell trafficking (65) and for Th2 (but not Th1) homing, as well as Th2-induced allergic lung disease (66). Interestingly, certain CD11a polymorphisms critically influence Th2 homing (67).

In myeloid cells such as macrophages, beta2-integrins can initiate intracellular signaling pathways leading to cytokine secretion, either by themselves or together with Toll like receptors (TLRs) (21, 68, 69). In addition, many neutrophil functions such as cytokine release and oxidative burst are dependent on beta2-integrins (70–73). CD11b/CD18 and CD11c/CD18 are receptors for complement component iC3b and are essential for phagocytosis of opsonized pathogens in neutrophils and other phagocytic cells, where they induce a RhoA-dependent phagocytic pathway (74–76). The differential roles of these two highly similar integrins have been studied in vivo in CD11b−/− and CD11c−/− mice. The results indicate that CD11b/CD18 is involved in neutrophil functions and in the anti-inflammatory functions of macrophages, whereas CD11c/CD18 is more relevant in the regulation of macrophage inflammatory functions (77). Recently, beta2-integrins has been shown to be required for recruitment of monocytes, as well as hematopoiesis of these cells during Schistosome infection, and a low expression of beta2-integrins correlates with increased parasite burden in a murine model of the disease (78).

**BETA2-INTEGRINS IN IMMUNE SUPPRESSION**

In addition to their well-characterized role in mediating cellular interactions and promoting pro-inflammatory...
signaling, beta2-integrins have also been associated with many immunosuppressive functions (20) (Figure 1). Beta2-integrins can inhibit TLR signaling in macrophages through negative feedback loops, either directly or indirectly, through the anti-inflammatory cytokine IL-10 (79, 80). TLR stimulation leads to PI(3)K- and RapL-mediated inside-out activation of CD11b/CD18. Integrin outside-in signaling activates Src/Syk, leading ultimately to degradation of the important TLR signaling transducers MyD88 and TRIF and downregulation of TLR signaling (80). The mechanism of CD11b/CD18-dependent modulation of TLR responses has been shown to involve inhibition of the NF-κB pathway and activation of the p38 MAPK pathway (81). Beta2-integrins have been found to repress DC-mediated T cell activation (82–84), and the presence of CD11b/CD18 on APCs has been demonstrated to suppress Th17 differentiation and lead to immune tolerance (85, 86).

Recently, CD11b/CD18-expressing neutrophils have been shown to suppress T cell-dependent influenza pathology in vivo by limiting T cell proliferation (87). The immunoregulatory role of leukocyte integrins may be taken advantage of by the macrophage-infecting bacterium Francisella tularensis, which is phagocytosed in a CD11b-dependent manner and uses the CD11b-driven inhibition of inflammasome activation to evade the innate immune system (88). In addition to opsonized bacteria, CD11b/CD18, and CD11c/CD18 also recognize iC3b-opsonized apoptotic cells, which leads to inhibition of proinflammatory cytokine production through NF-κB inhibition (89).

A series of important findings of the immunoregulatory roles of beta2-integrins has been produced using mice where the kindlin-3 binding site in the CD18-chain has been mutated, leading to decreased expression of CD18 (the beta2-integrin-chain) is either diminished or abolished. In LAD-I, mutations in kindlin-3 prevents it from activating beta2-integrins (especially CD11b) have an equally significant role in repressing the body's reactions against self. Therefore, manipulating integrin activation pharmacologically could be an efficient therapeutic approach in treating certain inflammatory or autoimmune diseases.

**LEUKOCYTE ADHESION DEFICIENCIES**

The importance of beta2-integrins in immunity is highlighted by the rare genetic diseases known as Leukocyte adhesion deficiencies type I and type III (LAD-I and LAD-III) (Table 1). LAD syndromes are a group of congenital autosomal-recessive diseases with immune deficiency condition resulting in impaired leukocyte adhesion and migration. In LAD-I, the expression of CD18 (the beta2-integrin-chain) is either diminished or abolished. In LAD-III, mutations in kindlin-3 prevents it from activating beta2-integrins. Both conditions present partly with similar symptoms, which include leukocytosis and a lack of neutrophil extravasation from the blood stream into tissues. Consequently, the patients end up suffering from recurrent life-threatening infections, unless they receive a hematopoietic stem cell transplant (HSCT) (97). LAD-II is a selectin- (rather than integrin) related disease which is caused by a failure in selectin ligand expression (98) and will not be discussed further here.

**LAD I**—Over 200 mutations have been identified in LAD-I patients which cause decreased expression of CD18. The severity of the disease varies according to the functionality of the beta2-integrin (99). LAD-I patients suffer from life threatening bacterial and fungal infections early in life, and especially neutrophil trafficking is reduced into the inflamed tissue. In a recent (2018) review of all published LAD cases before 2017 (323 cases) (100) it was reported that the most common infections in severe LAD-I (<2% CD18 expression) were respiratory tract infections (including pneumonia), sepsis, and otitis media whilst in LAD-I with moderate CD18 expression the most common infections were periodontal infection, otitis media and sepsis. Perianal skin infections and necrotic skin ulcers were reported in both groups. Delayed umbilical cord detachment is common. In addition, patients suffer from symptoms such as delayed wound healing.

For severe LAD-I, survival beyond 2 years of age was only 39%, showing that severe LAD-I remains a life-threatening condition (100). The prognosis for LAD-I with moderate CD18 expression is much better, with survival over 2 years and beyond (to adulthood) for over 90% of cases with >4% CD18 expression (100, 101).

HSCT remains the only cure for patients expressing very low (<1–2%) levels of CD18 protein in leukocytes, but unfortunately transplant-related mortality remains high (19% for all groups in LAD-I) (100).
**TABLE 1 | Beta2-integrins in immunodeficiency and inflammatory disease.**

| Disease          | Symptoms                                                                 | Beta2-integrin defects                                                                 | Impaired immune functions                                                                 |
|------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| LAD I            | Bacterial and fungal infections in skin and other tissues; Delayed wound healing. Periodontitis, Leukocytosis, Candidiasis | Mutation in CD18 chain leading to decreased or non-existent expression of beta2-integrins | Decreased neutrophil trafficking to the site of inflammation. Defective adaptive immune responses (especially in T cells) Impaired restriction of inflammatory responses (e.g., cytokine release) |
| LAD III          | Same as LAD I but also Glanzmann thrombasthenia. Osteoporosis             | Mutation in kindlin-3 protein, leading to incorrect activation of beta1-, beta2-, and beta3-integrins | In addition to LAD I functions: Impaired platelet activation and blood clotting Impaired osteoclast function |
| SLE (Systemic Lupus Erythematosus) | Severe fatigue, Joint pain and swelling, Headaches, Rashes on cheeks and nose, Hair loss, Anemia, Blood-clotting problems | R77H, P1146S and A868V substitutions in CDllb                                           | Impaired ligand binding and phagocytosis(R77H) Increased adhesion, spreading, and migration (P1146S) Increased pro-inflammatory cytokine release (R77H and P1146S) |

Beta2-integrin deficient mice have similar immune defects as LAD-I patients (102). These mice have been useful to investigate the role of beta2-integrins and their function in different leukocytes (102, 103).

**LAD-III**—LAD-III is a much rarer disease than LAD-I, with <40 patients reported worldwide (104). Patients suffer from similar symptoms as LAD-I patients, e.g., recurrent bacterial infections including bacteremias, pulmonary infections, omphalitis, and other soft tissue infections. Also fungal infections have been reported. However, unlike LAD-I patients, LAD-III patients additionally have Glanzmann type thrombasthenia, a bleeding disorder. Transfusions have been performed in >90% of cases as bleeding is a hallmark of the disease and remains a serious complication (105). In addition, recombinant factor VIIa has been used successfully in LAD-III to treat bleeding events (105). Furthermore, patients can suffer from osteoporosis, due to deficient integrin-mediated osteoclast bone resorption.

LAD-III patients have normal integrin expression but carry mutations in the FERM3 gene encoding kindlin-3 protein (106). Since kindlin-3 binds to beta1, beta2, and beta3-integrins and regulates their function, patients display more complex symptoms compared to LAD-I patients. In platelets kindlin-3 is required for αIIβ3-integrin-mediated formation of blood clots. Kindlin-3 further regulates normal bone regeneration by several integrins. As for LAD-I, the only curative treatment for LAD-III is HSCT, and HSCT-related mortality remains high [22%, (105)].

Kindlin-3 has a central role in immunity which is shown by the phenotype of the kindlin-3 deficient mice (12, 38). These mice die early after birth because of excessive bleeding. These mice, as well as mice carrying a mutation in the kindlin-3 binding site in beta2-integrin cytoplasmic tail (TTT/AAA-beta2-integrin KI mice) have shown a crucial role of kindlin-3 and beta2-integrins in the regulation of immune cells (35, 36, 51, 56).

**LAD AND INFLAMMATION**

Many of the symptoms in LAD patients are thought to be caused by defective leukocyte (especially neutrophil) trafficking into inflamed tissue. However, not all symptoms in LAD-I are due to defective leukocyte-mediated immune surveillance. Instead, periodontitis and associated bone loss in LAD-I has recently been shown to be associated with an increased inflammatory response, with excessive production of IL-17 and related cytokines (107), and blocking the IL-17 cytokine response reduces symptoms in a LAD-I patient (108). In addition, particular inflammatory disorders (e.g., colitis) have been reported in LAD-patients (109–111). This indicates that at least some pathological symptoms in LAD-I patients are caused by dysregulated inflammatory responses. The increased IL-17 production in LAD-I patients may be—at least in part—due to defective neutrophil recruitment into tissues e.g., dysregulation of the so called “neutrostat”, which senses and regulates neutrophil numbers in vivo (107). However, beta2-integrins have been shown to directly restrict cytokine responses in many types of immune cells, such as macrophages (80), DCs (51), and mast cells (36), and to restrict Th1 (51) and Th17 (85) polarization in vivo. In addition, functional beta2-integrins restrict expression of cytokines in a skin inflammation model, although neutrophil trafficking is relatively normal in this model (36). Dysregulated cytokine responses may therefore contribute to the paradoxical increase in inflammation (periodontitis, colitis) in LAD-I patients (107, 109, 110, 112).

**THERAPEUTIC TARGETING OF BETA2-INTEGRINS**

Because of the crucial role of beta2-integrins in leukocyte functions such as leukocyte recruitment, beta2-integrins have been considered attractive targets in inflammatory disease such as psoriasis, arthritis, and multiple sclerosis [reviewed in Mitroulis et al. (113)]. Indeed, an antibody against alpha1-integrin chain, efalizumab, has previously been in clinical use in psoriasis (113). However, the drug was withdrawn from the market in 2009 because it was associated with serious side effects, e.g., reactivation of latent John Cunningham (JC) virus infection and resulting progressive multifocal leukoenphalopathy (PML). Therefore, therapeutic blocking of beta2-integrins in disease may be difficult because these molecules play such multifaceted roles in central immune reactions.
CONCLUSIONS AND FUTURE PERSPECTIVES

Beta2-integrins are of crucial importance for leukocyte trafficking and immune cell activation, but interestingly play a role in immune suppression as well. Consequently, dysfunctional or absent integrins are linked not only to immune deficiency disease but also to inflammatory disease, thereby contributing to both ends of the spectrum of immune-related diseases. A better understanding of the disease processes where dysfunctional beta2-integrins are involved may provide novel drug targets for immunodeficiency and inflammatory disease symptoms (95, 108).

REFERENCES

1. Hynes RO. Integrins: a family of cell surface receptors. Cell (1987) 48:549–54. doi: 10.1016/0092-8674(87)90233-9
2. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature (1984) 309:30–3. doi: 10.1038/309030a0
3. Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol. (1986) 137:1270–4.
4. Patarrooyo M, Clark EA, Prieto J, Kantor C, Gahmberg CG. Identification of a novel adhesion molecule in human leukocytes by monoclonal antibody LB-2. FEBS Lett. (1987) 210:127–31. doi: 10.1016/0014-5793(87)81321-2
5. Nishida N, Xie C, Shimaoka M, Cheng Y, Walz T, Springer TA. Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. Immunity (2006) 25:583–94. doi: 10.1016/j.immuni.2006.07.016
6. Li J, Springer TA. Integrin extension enables ultra-sensitive regulation by cytoskeletal force. Proc Natl Acad Sci USA. (2017) 114:4685–4690. doi: 10.1073/pnas.1704171114
7. Li J, Su Y, Xia W, Qin Y, Humphries MJ, Vestweber D, et al. Conformational equilibria and intrinsic affinities define integrin activation. EMBO J. (2017) 36:629–45. doi: 10.15252/embj.201695803
8. Schurpf T, Springer TA. Regulation of integrin affinity on cell surfaces. EMBO J. (2011) 30:4712–27. doi: 10.1038/emboj.2011.333
9. Moore TL, Aaron J, Chew TL, Springer TA. Measuring integrin conformational change on the cell surface with super-resolution microscopy. Cell Rep. (2018) 22:1903–12. doi: 10.1016/j.celrep.2018.01.062
10. Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science (2003) 301:1720–5. doi: 10.1126/science.1084174
11. Campbell ID, Ginsberg MH. The talin-tail interaction places integrin activation on FERM ground. Trends Biochem Sci. (2004) 29:429–35. doi: 10.1016/j.tibs.2004.06.005
12. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. (2008) 14:325–30. doi: 10.1038/nm1722
13. Nordenfelt P, Elliott HL, Springer TA. Coordinated integrin activation on FERM ground. Trends Biochem Sci. (2012) 37:241–69. doi: 10.1016/j.tibs.2012.04.004
17. Chatterjee D, Zhipeing LL, Tan SM, Bhattacharjya S. Interaction analyses of the integrin beta2 cytoplasmic tail with the F3 FERM domain of talin and 14-3-3zeta reveal a ternary complex with phosphorylated tail. J Mol Biol. (2016) 428:4129–42. doi: 10.1016/j.jmb.2016.08.014
18. Fagerholm SC, Hilden TJ, Nurmi SM, Gahmberg CG. Specific integrin alpha and beta chain phosphorylations regulate LFA-1 activation through affinity-dependent and -independent mechanisms. J Cell Biol. (2005) 171:765–15. doi: 10.1083/jcb.200504016
19. Tan SM. The leucocyte beta2 (CD11b) integrins: the structure, functional regulation and signalling properties. Biochim. (2012) 32:241–69. doi: 10.1042/BSR20110101
20. Schittenhelm L, Hilkens CM, Morrison VL. beta2 integrins as regulators of dendritic cell, monocyte, and macrophage function. Front Immunol. (2017) 8:1866. doi: 10.3389/fimmu.2017.01866
21. Wolf D, Anto-Michel N, Blankenbach H, Wiedemann A, Buscher K, Hohmann JD, et al. A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense. Nat Commun. (2018) 9:525. doi: 10.1038/s41467-018-02896-8
22. Kawamoto E, Masui-Ito A, Eguchi A, Soe ZY, Praujabjinda O, Darkwah S, et al. Integrin and PD-1 ligand expression on circulating extracellular vesicles in systemic inflammatory response syndrome and sepsis. Shock (2018), doi: 10.1097/SHK.0000000000001228. [Epub ahead of print].
23. Gahmberg CG, Fagerholm SC, Nurmi SM, Chavakis T, Marchesan S, Gronholm M. Regulation of integrin activity and signalling. Biochim Biophys Acta (2009) 1790:431–44. doi: 10.1016/j.bjba.2009.03.007
24. Klaus Ley CL, Myron I, Cybulsky, sussan noursargh getting to the site of inflammation: the leucocyte adhesion cascade updated. Nat Rev Immunol. (2007) 7:678–89. doi: 10.1038/nri2156
25. Yago T, Zhang N, Zhao L, Abrams CS, McEver RP. Selectins and chemokines use shared and distinct signals to activate β2 integrins in neutrophils. Blood Adv. (2018) 2:731–44. doi: 10.1182/bloodadvances.2017015602
26. McEver RP, Zu C. Rolling cell adhesion. Annu Rev Cell Dev Biol. (2010) 26:363–96. doi: 10.1146/annurev.cellbio.042308.113238
27. Jiang G, Gianione G, Critchley DR, Fukushima E, Sheetz MP. Two-piconewton slip bond between fibronectin and the cytoskeleton depends on talin. Nature (2003) 424:334–7. doi: 10.1038/nature01805
28. Kong F, Garcia AJ, Mouad AP, Humphries MJ, Zhu C. Demonstration of catch bonds between an integrin and its ligand. J Cell Biol. (2009) 185:1275–84. doi: 10.1083/jcb.200810002
29. Phillipson M, Heit B, Colaruso P, Liu L, Ballantyne CM, Kubes P. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J Exp Med. (2006) 203:2569–75. doi: 10.1084/jem.20060925
30. Sun Z, Guo SS, Fassler R. Integrin-mediated mechanotransduction. J Cell Biol. (2016) 215:445–56. doi: 10.1083/jcb.201609037
31. Manevich-Mendelson E, Grabovsky V, Feigelson SW, Cinamon G, Gore Y, Goveze G, et al. Talin1 is required for integrin-dependent B lymphocyte homing to lymph nodes and the bone marrow but not

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

ACKNOWLEDGMENTS

The author’s laboratory has funding from Academy of Finland, Sigrid Juselius foundation, HILIFE/University of Helsinki, Liv och Hålsa, Svenska Kulturfonden, and Magnus Ehrnrooth foundation. We thank Heidi Harjunpää for useful comments on the manuscript.
for follicular B-cell maturation in the spleen. *Blood* (2010) 116:5907–18. doi: 10.1182/blood-2010-06-293506
32. Wernimont SA, Wiemer AJ, Bennin DA, Monkley SJ, Ludwig T, Critchley DR, et al. Contact-independent T cell activation and T cell stopping require talin. *J Immunol*. (2011) 187:2506–7. doi: 10.4049/jimmunol.1102028
33. Lefort CT, Rossaint J, Moser M, Petrich BG, Zarbock A, Monkley SJ, et al. Distinct roles for talin-1 and kindlin-3 in LFA-1 extension and affinity regulation. *Blood* (2012) 119:4275–82. doi: 10.1182/blood-2011-08-373118
34. Klapholz B, Brown NH. Talin - the master of integrin adhesions. *J Cell Sci.* (2017) 130:2435–46. doi: 10.1242/jcs.190991
35. Morrison VL, Macpherson M, Savinco F, Lan K, Prescott A, Fagerholm SC. The beta2 integrin-kindlin-3 interaction is essential for T cell homing but dispensable for T-cell activation in vivo. *Blood* (2013) 122:1426–37. doi: 10.1182/blood-2013-02-489988
36. Savinco TS, Morrison VL, Uotila LM, Wolfch CH, Alenuis HT, Fagerholm SC. Functional Beta2-integrins restrict skin inflammation in vivo. *J Invest Dermatol.* (2015) 135:2249–57. doi: 10.1038/jid.2015.164
37. Moretti FA, Moser M, Lyck R, Abadier M, Ruppert R, Engler M, et al. Kindlin-3 regulates integrin activation and adhesion reinforcement of effector T cells. *Proc Natl Acad Sci USA*. (2011) 108:7005–10. doi: 10.1073/pnas.1108321110
38. Moser M, Bauer M, Schmid S, Ruppert R, Schmidt S, Sixt M, et al. Kindlin-3 is required for beta2 integrin-mediated leukocyte adhesion to endothelial cells. *Nat Med* (2009) 15:380–5. doi: 10.1038/nm.1921
39. Moretti FA, Klapproth S, Ruppert R, Maegraf A, Weber J, Pick R, et al. Differential requirement of kindlin-3 for T cell progenitor homing to the non-vascularized and vascularized thymus. *eLife* (2018) 7:e35816. doi: 10.7554/eLife.35816
40. Calderwood DA, Zent R, Grant R, Rees DJ, Hynes RO, et al. The molecular basis of filamin binding to integrins and competition with talin. *Mol Cell*. (2006) 21:337–47. doi: 10.1016/j.molcel.2006.01.011
41. Liu J, Das M, Yang J, Ilyichanda SS, Yakubenko VP, Plow EF, et al. Structural mechanism of integrin inactivation by filamin. *Nat Struct Mol Biol* (2015) 22:383–9. doi: 10.1038/nsmb.2999
42. Aitken H, Pollitt AV, Begonia AJ, Weber SE, Duerchschild M, Wagner DG, et al. A novel interaction between Filna and Syk regulates platelet ITAM-mediated receptor signaling and function. *J Exp Med* (2010) 207:1967–79. doi: 10.1084/jem.20100222
43. Savinco T, Guenther C, Uotila LM, Llort Asens M, Savinco T, Fagerholm SC. Optimal T cell activation and B cell antibody responses in vivo require the interaction between leukocyte function-associated antigen-1 and T-3. *J Immunol*. (2015) 195:105–15. doi: 10.4049/jimmunol.1402741
44. Walling BL, Kim M. LFA-1 in T cell migration and differentiation. *Front Immunol*. (2015) 6:952. doi: 10.3389/fimmu.2015.00952
45. Verma NK, Fazil MH, Orso SG, Chalasani ML, Low IH, Kottaissamy A, et al. LFA-1/ICAM-1 ligations in human T cells promotes T cell polarization through a GSK3beta signaling-dependent notch pathway. *J Immunol*. (2016) 197:1018–18. doi: 10.4049/jimmunol.1501264
46. Verma NK, Dempsey E, Long A, Davies A, Barry SP, Fallon PG, et al. Leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction induces a novel genetic signature resulting in T-cells refractory to transforming growth factor-beta signaling. *J Biol Chem*. (2012) 287:27204–16. doi: 10.1074/jbc.M112.376616
47. Boutet M, Gauthier L, Leclerc M, Gros G, Montreville V, Thoret N, et al. TGfβeta signaling interacts with CD103 integrin signaling to promote T-lymphocyte accumulation and antitumor activity in the lung tumor microenvironment. *Cancer Res*. (2016) 76:1757–69. doi: 10.1158/0008-5472.CAN-15-1545
48. Capence T, Walling BL, Lim K, Kim KD, Bae S, Chung HI, et al. A novel intracellular pool of LFA-1 is critical for asymmetric CD8(+) T cell activation and differentiation. *J Cell Biol*. (2017) 216:3817–29. doi: 10.1083/jcb.201609072
49. Meli AP, Fontes G, Avery DT, Leddon SA, Tam M, Elliot M, et al. The Integrin LFA-1 controls T follicular helper cell generation and maintenance. *Immunity* (2016) 45:831–46. doi: 10.1016/j.immuni.2016.09.018
50. Klaen IR, Remediros KA, Kim SH, Metz PJ, Lopez J, Mack LA, et al. Talin plays a critical role in the maintenance of the regulatory T cell pool. *J Immunol*. (2017) 198:4639–51. doi: 10.4049/jimmunol.1601165
51. Verma NK, Kelleher D. Not just an adhesion molecule: LFA-1 contact tunes the T lymphocyte program. *J Immunol*. (2017) 199:1213–21. doi: 10.4049/jimmunol.1700495
52. Schmits R, Kundig TM, Baker DM, Shumaker G, Simard JJ, Duncan G, et al. LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. *J Exp Med*. (1996) 183:1415–26. doi: 10.1084/jem.183.4.1415
53. Lee SH, Prince JE, Rais M, Kheradmand F, Ballantyne CM, Weitz-Schmidt G, et al. Developmental control of integrin expression regulates Th2 effector homing. *J Immunol*. (2008) 180:4656–67. doi: 10.4049/jimmunol.180.7.4656
54. Knight JM, Lee SH, Roberts L, Smith CW, Weiss ST, Kheradmand F, et al. CD11a polymorphisms regulate TH2 cell homing and TH2-related disease. *J Allergy Clin Immunol*. (2014) 133:189–97 e1–8. doi: 10.1016/j.jaci.2013.03.049
55. Rezzaonico R, Imperi V, Cicheporicte R, Dayer JM. Ligation of CD11b and CD11c beta(2) integrins by antibodies or soluble CD23 induces macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-beta production in primary human monocytes through a pathway dependent on nuclear factor-kappaB. *Blood* (2001) 97:2932–40. doi: 10.1182/blood.V97.20.2932
56. Lin GS, Bennett J, Woolard KJ, Szajna M, Fossati-Jimack L, Taylor PR, et al. Integrin CD11b positively regulates TLR4-induced signalling pathways.
in dendritic cells but not in macrophages. *Nat Commun*. (2014) 5:5039. doi: 10.1038/ncomms4039

70. Anderson KE, Boyle KB, Davidson K, Chessa TA, Kulkarni S, Jarvis GE, et al. CD18-dependent activation of the neutrophil NADPH oxidase during phagocytosis of *Escherichia coli* or *Staphylococcus aureus* is regulated by class III but not class I or II PI3Ks. *Blood* (2008) 112:2502–11. doi: 10.1182/blood-2008-04-149450

71. Van Zifflè JA, Lowell CA. Neutrophil-specific deletion of Syk kinase results in reduced host defense to bacterial infection. *Blood* (2009) 114:4871–82. doi: 10.1182/blood-2009-05-220806

72. Zhou MJ, Brown EJ. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RII cooperates in a neutrophil respiratory burst: requirement for Fc gamma RII and tyrosine phosphorylation. *J Cell Biol* (1994) 125:1407–16. doi: 10.1083/jcb.125.6.1407

73. Wilson ZS, Ahs LB, Serratelli WS, Belley MD, Lomas-Neira J, Sen M et al. Activated beta2 integrins restrict neutrophil recruitment during murine acute Pseudomonal Pneumonia. *Am J Respir Cell Mol Biol*. (2017) 56:620–7. doi: 10.1165/rcmb.2016-0215OC

74. Dupuy AG, Caron E. Integrin-dependent phagocytosis: spreading from microbeads to new concepts. *J Cell Sci*. (2008) 121:1773–83. doi: 10.1242/jcs.018036

75. Underhill DM, Goodridge HS. Information processing during phagocytosis. *Biomed Res Int*. (2017) 2017:9042851. doi: 10.1155/2017/9042851

76. Rosales C, Uribe-Querol E. Phagocytosis: a fundamental process in immunity. *Biomom Res Int*. (2017) 2017:9042851. doi: 10.1155/2017/9042851

77. Jawhara S, Pliskuta E, Cao W, Plow EE, Soloviev DA. Distinct effects of integrins alphaBeta2 and alphaBeta2 on leukocyte subpopulations during inflammation and antimicrobial responses. *Infect Immun*. (2017) 85:e00644-16. doi: 10.1128/IAI.00644-16

78. Souza COS, Espindola MS, Fontanari C, Prado MKB, Frantz FG, Rodrigues V, et al. CD18 regulates monocyte hematopoiesis and promotes resistance to experimental *Schistosoma mansoni*. *Front Immunol*. (2018) 9:1970. doi: 10.3389/fimmu.2018.01970

79. Wang L, Gordon RA, Huynh L, Su X, Park Min KH, Han J, et al. Indirect inhibition of Toll-like receptor and type 1 interferon responses by ITAM-coupled receptors and integrins. *Immunity* (2010) 32:518–30. doi: 10.1016/j.immuni.2010.03.014

80. Han C, Jin J, Xu S, Liu H, Li N, Cao X. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. *Nat Immunol*. (2010) 11:734–42. doi: 10.1038/ni.1908

81. Yee NK, Hamerman J. A. beta(2) integrins inhibit TLR responses by ITAM-coupled receptors and integrins. *Blood* (2009) 113:1837–46. doi: 10.1182/blood-2008-05-158059

82. Varga G, Balkow S, Wild MK, Stadtbaeumer A, Krummen M, Rothoeft T, et al. LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming. *J Exp Med*. (2003) 197:675–86. doi: 10.1084/jem.2002292

83. Saultier P, Szepetowski S, Canault M, Falaise C, Poggi M, Sucron P, et al. Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation. *Haematologica* (2018) 103:264–e267. doi: 10.3324/haematol.2017.186304

84. Rognoni E, Ruppert R, Fassler R. The kindlin family: functions, signaling properties and implications for human disease. *J Cell Sci*. (2016) 129:17–27. doi: 10.1242/jcs.161190
107. Moutsopoulos NM, Konkel J, Sarmadi M, Eskan MA, Wild T, Dutzan N, et al. Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. *Sci Transl Med.* (2014) 6:229ra40. doi: 10.1126/scitranslmed.3007696

108. Moutsopoulos NM, Zerbe CS, Wild T, Dutzan N, Brenchley L, DiPasquale G, et al. Interleukin-12 and interleukin-23 blockade in leukocyte adhesion deficiency type 1. *N Engl J Med.* (2017) 376:1141–6. doi: 10.1056/NEJMoa1612197

109. Uzel G, Kleiner DE, Kuhns DB, Holland SM. Dysfunctional LAD-1 neutrophils and colitis. *Gastroenterology* (2001) 121:958–64. doi: 10.1053/gast.2001.28022

110. Uzel G, Tng E, Rosenzweig SD, Hsu AP, Shaw JM, Horwitz ME, et al. Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1). *Blood* (2008) 111:209–18. doi: 10.1182/blood-2007-04-082552

111. Wolach B, Garriédi R, Wolach O, Stauber T, Abuzaitoun O, Kuperman A, et al. Leucocyte adhesion deficiency-A multicentre national experience. *Eur J Clin Invest.* 49:e13047. doi: 10.1111/eci.13047

112. D’Agata ID, Paradis K, Chad Z, Bonny Y, Seidman E. (1996). Leucocyte adhesion deficiency presenting as a chronic ileocolitis. *Gut* (1988) 39:605–8. doi: 10.1136/gut.39.4.605

113. Mitroulis I, Alexaki VI, Kourtzelis I, Ziogas A, Hajishengallis G, Chavakis, T. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. *Pharmacol Ther.* (2015) 147:123–35. doi: 10.1016/j.pharmthera.2014.11.008

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Fagerholm, Guenther, Llort Asens, Savinko and Uotila. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.